U.S. Markets closed

COMPASS Pathways plc (CMPS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
34.34-0.01 (-0.03%)
At close: 4:00PM EDT

34.45 +0.11 (0.32%)
After hours: 7:31PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close34.35
Open34.50
Bid34.25 x 800
Ask35.88 x 800
Day's Range33.81 - 35.45
52 Week Range22.51 - 61.69
Volume217,469
Avg. Volume400,321
Market Cap1.259B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.55
Earnings DateMar 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est70.60
  • The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split
    Benzinga

    The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 14) 10x Genomics, Inc. (NASDAQ: TXG) Affimed N.V. (NASDAQ: AFMD) Bio-Techne Corporation (NASDAQ: TECH) - announced out-licensing of antibody treatment candidate to Xencor, Inc. (NASDAQ: XNCR) BioNTech SE (NASDAQ: BNTX) - reacted to increased EU orders for its COVID-19 vaccine in the wake of the Johnson & Johnson (NYSE: JNJ) setback Globus Medical, Inc. (NYSE: GMED) Medpace Holdings, Inc. (NASDAQ: MEDP) Medtronic plc (NYSE: MDT) Merit Medical Systems, Inc. (NASDAQ: MMSI) Natus Medical Incorporated (NASDAQ: NTUS) NuVasive, Inc. (NASDAQ: NUVA) PLx Pharma Inc. (NASDAQ: PLXP) PPD, Inc. (NASDAQ: PPD) - moved on rumors of a potential buyout by Thermo Fisher Scientific Inc. (NYSE: TMO) ShockWave Medical, Inc. (NASDAQ: SWAV) Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) Zimmer Biomet Holdings, Inc. (NYSE: ZBH) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 14) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) Celyad Oncology SA (NASDAQ: CYAD) Design Therapeutics, Inc. (NASDAQ: DSGN) Kronos Bio, Inc. (NASDAQ: KRON) Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Metacrine, Inc. (NASDAQ: MTCR) Millendo Therapeutics, Inc. (NASDAQ: MLND) Nabriva Therapeutics plc (NASDAQ: NBRV) Osmotica Pharmaceuticals plc (NASDAQ: OSMT) Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) Stocks In Focus Regenxbio Doses First Patient In Gene Therapy Study REGENXBIO Inc. (Nasdaq: RGNX) said it dosed the first patient in Cohort 3 of the ongoing Phase I/2 trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II, also known as Hunter Syndrome, in patients up to five years old. RGX-121 is an investigational one-time gene therapy designed to deliver the gene that encodes the iduronate-2-sulfatase enzyme using the AAV9 vector. RGX-121 is administered directly to the central nervous system. The stock gained 5.4% to $37.25 in after-hours trading. Novavax Confirms Participation In Combination COVID-19 Vaccine Study In UK Novavax, Inc. (NASDAQ: NVAX) said it is participating in a newly expanded investigator-initiated Phase 2 clinical trial called "Comparing COVID-19 Vaccine Schedule Combinations – Stage 2," dubbed Com-COV2, to be conducted by the University of Oxford and supported by the U.K. Vaccines Taskforce. Novavax's recombinant protein vaccine candidate NVX-CoV2373 is one of four COVID-19 vaccines that will be studied to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19. The stock was up 2.18% premarket to $205.72. Pacira Initiates Legal Proceedings Against Publication Pacira BioSciences, Inc. (NASDAQ: PCRX) said it has filed a lawsuit against the American Society of Anesthesiologists and various other defendants, seeking pecuniary damages and the retraction of three articles that it said create the false and misleading impression that its Exparel is not an effective analgesic. The stock was down 1.35% to $68.49 in premarket trading Thursday. Bristol-Myers Squibb Announces European Approval For Kidney Cancer Combo Treatment Bristol-Myers Squibb (NYSE: BMY) said the European Commission has approved its Opdivo in combination with Exelixis, Inc.'s (NASDAQ: EXEL) Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma. Merck Pulls Plug On COVID-19 Asset, Shelves Study of Another In Hospitalized COVID-19 Patients Merck (NYSE: MRK) and partner Ridgeback Biotherapeutics said a decision has been made to proceed with the Phase 3 portion of MOVe-OUT in outpatients with COVID-19 evaluating the 800 mg dose of molnupiravir twice daily. Yet the companies have decided not to proceed with the Phase 3 study of molnupiravir in hospitalized patients, as data from MOVe-IN indicate that molnupiravir is unlikely to demonstrate a clinical benefit in this population. Separately, Merck announced the discontinuation of development of MK-7110 for the treatment of hospitalized patients with COVID-19. The company acquired MK-7110 in December 2020 through its acquisition of OncoImmune. View more earnings on IBB Related Link: The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight Roche Reports Positive Long-Term Phase 2/3 Data For Spinal Muscular Dystrophy Treatment In Infants Roche Holding AG (OTC: RHHBY) announced new two-year data from Part 2 of FIREFISH, a Phase 2/3 global study evaluating Evrysdi in infants ages 1-7 months at enrollment with symptomatic Type 1 spinal muscular atrophy. The data shows Evrysdi continued to improve motor function between months 12 and 24, including the ability to sit without support. The study also showed Evrysdi continued to improve survival, improve ability to feed orally and reduce the need for permanent ventilation. Exploratory data suggested Evrysdi continued to improve the ability to swallow and reduce hospitalizations compared to the natural course of Type 1 SMA. Safety for Evrysdi was consistent with its established safety profile. Neuronetics Names Robert Cascella As Chairman Neuronetics, Inc. (NASDAQ: STIM) announced that Brian Farley will retire from its board and his role as chairman following its annual shareholder meeting scheduled for May 27. The company named Robert Cascella, who joined the board on April 1, as chairman of its board following Farley's retirement. The board will now have seven members. InspireMD Announces 1-For-15 Reverse Split InspireMD, Inc. (NYSE: NSPR) announced a 1-for-15 reverse split of its common stock effective April 26. Beginning on April 27, the stock will trade on the NYSE American on a split-adjusted basis. The stock was down 9.15% premarket at 50 cents. Compass Announces Publication Of Positive Results For Depression Drug COMPASS Pathways plc (NASDAQ: CMPS) announced publication of the results of an exploratory study in the New England Journal of Medicine showing signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram for major depressive disorder. COMP360 is Compass' proprietary formulation of synthetic psilocybin. AbCellera Announces Collaboration Agreement For Antibody Drug Discovery AbCellera Biologics Inc. (NASDAQ: ABCL) and Empirico announced a strategic multi-target discovery collaboration. Through each company's proprietary technologies, the multi-target collaboration leverages hyper-scale datasets, machine learning and advanced computation to both identify high-value, genetically validated drug targets and discover novel therapeutic antibodies, the companies said. Under the terms of the agreement, Empirico will have the rights to develop and commercialize novel antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products from Empirico. Abcellera shares were up 2.65% to $29 in premarket trading Thursday. On The Radar Clinical Readouts Chinook Therapeutics, Inc. (NASDAQ: KDNY) will present at the the International Society of Nephrology's World Congress of Nephrology with Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and Part 2 of the ongoing Phase 1 study of BION-1301 in immunoglobin A nephropathy, as well as data from the Phase 1 intravenous to subcutaneous bioavailability study in healthy volunteers. Earnings Affimed N.V. (NASDAQ: AFMD) (before the market open) Centogene N.V. (NASDAQ: CNTG) Centogene N.V. (NASDAQ: CNTG) (before the market open) Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) Related Link: Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates See more from BenzingaClick here for options trades from BenzingaThe Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For GileadThe Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
    GlobeNewswire

    New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder

    Study concludes that psilocybin findings should be explored further in larger studiesLondon, UK, April 15, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed a study published in the New England Journal of Medicine (NEJM) yesterday, which showed signals of positive activity in COMP360 psilocybin compared with the standard antidepressant escitalopram, for major depressive disorder (MDD). The study was designed and conducted by a research team at Imperial College London, using COMPASS’s COMP360 psilocybin. This was an exploratory, randomised, double-blind clinical study. Its aim was to compare the efficacy and mechanisms of action of psilocybin with a six-week course of escitalopram, a selective serotonin reuptake inhibitor (SSRI), for MDD. The study included 59 participants; 30 were randomly assigned to the psilocybin arm, and 29 to the escitalopram arm. Participants in the psilocybin arm received two doses of 25mg psilocybin three weeks apart, with psychological support delivered prior to, during and after each psilocybin administration, plus six weeks of daily placebo capsules. The escitalopram arm received two doses of 1mg psilocybin (presumed negligible effect) three weeks apart, with equivalent psychological support to the psilocybin arm, plus six weeks of daily escitalopram capsules, 10mg for the first three weeks titrated to 20mg for the following three weeks. The study authors, from Imperial College London, noted that the study was not powered to detect a difference between psilocybin and escitalopram. As reported in the NEJM, the primary efficacy measure, the change from baseline in the self-rated 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16) total score at six weeks, did not show a significant difference between the two groups, with a two point difference favouring the psilocybin group compared with the escitalopram group. This trend favouring psilocybin was present from week one. Secondary outcomes including clinician-rated depression scales, response and remission, signalled the antidepressant effects of both agents; psilocybin showed numerical advantages on clinical measures compared with escitalopram. On the clinician-rated depression scales, the change from baseline at week six on the Montgomery-Asberg Depression Rating Scale (MADRS), showed a 7.2 point treatment difference favouring psilocybin, while the Hamilton Depression Rating Scale (HAM-D-17) showed a 5.3 point treatment difference favouring psilocybin. Response rates (a 50% or greater reduction on the QIDS-SR-16 total score from baseline) at week six were 70.2% for the psilocybin arm compared with 48.0% for the escitalopram arm, and remission rates (defined as a QIDS-SR-16 total score ≤5) at week six were 57.1% and 29.1%, respectively. Similar patterns favouring psilocybin were found in other secondary endpoints measuring work and social functioning, anxiety, avoidance, anhedonia, and wellbeing. Such secondary endpoints were uncorrected for multiplicity. Adverse event rates and severity were largely comparable across conditions. Adverse events in the psilocybin arm were typically transient, occurring and resolving within 24 hours of dosing days, with the most commonly reported adverse event being transient headaches. No Serious Adverse Events were reported. “In a field of research where it is very difficult to separate treatments in head-to-head comparative efficacy trials, this study found signals favouring psilocybin therapy over escitalopram. This is an encouraging investigator-initiated study that supports the need for additional clinical investigations in larger, well-powered studies to more accurately determine the efficacy of COMP360 psilocybin in MDD”, said George Goldsmith, CEO and Co-founder of COMPASS Pathways. “At COMPASS, we are already committed to a full clinical development programme of psilocybin therapy in treatment-resistant depression, and we know there is much more work to be done so that we can bring evidence-based innovation to patients who have run out of options in a number of mental health illnesses.” -Ends- About COMPASS Pathways COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, US. Our vision is a world of mental wellbeing. www.compasspathways.com Availability of other information about COMPASS Pathways Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933. Forward-looking statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, forward-looking statements can be identified by terminology such as “may”, “might”, “will”, “could”, “would”, “should”, “expect”, “intend”, “plan”, “objective”, “anticipate”, “believe”, “contemplate”, “estimate”, “predict”, “potential”, “continue” and “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things, the efficacy of COMP360 psilocybin therapy as a treatment for depression, COMPASS’s business strategy and goals, COMPASS’s ability to continue to advance its research, including COMP360, and COMPASS’s expectations regarding the benefits of its psilocybin therapy, including COMP360. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond COMPASS’s control and which could cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others: preclinical research and clinical development is lengthy and uncertain, and therefore our preclinical studies and clinical trials may be delayed or terminated, or may never advance to or in the clinic; and those risks and uncertainties described under the heading “Risk Factors” in COMPASS’s annual report on Form 20-F filed with the US Securities and Exchange Commission (SEC) on 9 March 2021 and in subsequent filings made by COMPASS with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, COMPASS disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on COMPASS’s current expectations and speak only as of the date hereof. Enquiries Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024 Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7423

  • COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference
    GlobeNewswire

    COMPASS Pathways plc to participate in 20th Annual Needham Virtual Healthcare Conference

    London, UK, April 09, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that George Goldsmith, Chairman, CEO and Co‑founder, and Lars Wilde, President, Chief Business Officer, and Co‑founder, will present a corporate update at 8:00am ET on 15 April at the 20th Annual Needham Virtual Healthcare Conference. Members of the COMPASS management team will also be holding 1:1 investor meetings. A live audio webcast of the presentation will be available on the "Events" page of the Investors section of the COMPASS website. A replay of the webcast will be available for 30 days following the event. For more information, please visit ir.compasspathways.com. -Ends- About COMPASS Pathways COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing. www.compasspathways.com Contacts: Media: Tracy Cheung, tracy@compasspathways.com, +44 7966 309024 Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401-290-7324 Attachment CMPS Needham Conference Participation - 4.8.21